Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
UBS analyst Danielle Antalffy maintains RxSight (NASDAQ:RXST) with a Neutral and lowers the price target from $16 to $8.
Stifel analyst Tom Stephan maintains RxSight (NASDAQ:RXST) with a Hold and lowers the price target from $9 to $8.
Needham analyst David Saxon maintains RxSight (NASDAQ:RXST) with a Buy and lowers the price target from $22 to $11.
RxSight (NASDAQ:RXST) affirms FY2025 sales outlook from $120.00 million-$130.00 million to $120.00 million-$130.00 million vs $...
RxSight (NASDAQ:RXST) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.17) by 52...
Morgan Stanley analyst Patrick Wood downgrades RxSight (NASDAQ:RXST) from Overweight to Equal-Weight and lowers the price ta...
Jefferies analyst Young Li downgrades RxSight (NASDAQ:RXST) from Buy to Hold and lowers the price target from $24 to $9.
